← All trials
NCT03436732
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2018
- Primary completion
- Nov 29, 2019
- Completion date
- Nov 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 23
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
- National Cancer Institute (NCI)Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.